Chronic refractory myofascial pain and denervation supersensitivity as global public health disease

BMJ Case Rep. 2016 Jan 13:2016:bcr2015211816. doi: 10.1136/bcr-2015-211816.

Abstract

Chronic pain with a 30.3% global prevalence significantly impacts universal health. Low back pain has a 9.4% prevalence worldwide causing the most widespread disability. Neck pain ranks 4th highest regarding years lived with disability with a 4.9% prevalence worldwide. The principal cause of pain in 85% of patients visiting a tertiary pain clinic has a myofascial origin. The root cause is multifocal neuromuscular ischaemia at myofascial trigger points from muscle tightening and shortening following spondylotic radiculopathy induced partial denervation. Chronic refractory myofascial pain (CRMP) is a neuromusculoskeletal disease needing management innovations. Using electrical twitch-obtaining intramuscular stimulation (eToims), we provide objective evidence of denervation supersensitivity in multiple myotomes as cause, aggravation and maintenance of CRMP. This study underscores our previous findings that eToims is safe and efficacious for long-term use in CRMP. eToims aids potential prevention (pre-rehabilitation), simultaneous diagnosis, treatment (rehabilitation) and prognosis in real time for acute and CRMP management.

Publication types

  • Case Reports

MeSH terms

  • Amines / therapeutic use
  • Analgesics / therapeutic use
  • Chronic Pain
  • Cyclohexanecarboxylic Acids / therapeutic use
  • Denervation*
  • Electric Stimulation Therapy / methods*
  • Gabapentin
  • Humans
  • Low Back Pain / etiology
  • Low Back Pain / therapy*
  • Male
  • Middle Aged
  • Myofascial Pain Syndromes / diagnosis
  • Myofascial Pain Syndromes / therapy*
  • Pain Measurement
  • Public Health
  • Radiculopathy
  • gamma-Aminobutyric Acid / therapeutic use

Substances

  • Amines
  • Analgesics
  • Cyclohexanecarboxylic Acids
  • gamma-Aminobutyric Acid
  • Gabapentin